Leszek Szczepanski

Author PubWeight™ 22.48^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.	N Engl J Med	2004	14.53
2	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.	Arthritis Rheum	2006	5.68
3	Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.	Am J Gastroenterol	2006	2.21
4	A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.	Pain Pract	2010	0.83
5	Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.	Pain Pract	2012	0.79
6	A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis.	Arthritis Res Ther	2014	0.78